Puma Biotechnology (NASDAQ:PBYI) Raised to "Strong-Buy" at StockNews.com

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) was upgraded by stock analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report released on Sunday.

Separately, HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Puma Biotechnology in a report on Friday, February 28th.

Puma Biotechnology Stock Performance

NASDAQ PBYI traded up $0.13 during trading hours on Friday, hitting $3.04. The company had a trading volume of 433,833 shares, compared to its average volume of 442,662. The firm has a market cap of $150.88 million, a P/E ratio of 6.33 and a beta of 1.29. The business has a fifty day simple moving average of $3.10 and a 200-day simple moving average of $3.04. Puma Biotechnology has a fifty-two week low of $2.23 and a fifty-two week high of $5.20. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The firm had revenue of $59.10 million for the quarter, compared to analyst estimates of $52.50 million. Equities analysts predict that Puma Biotechnology will post 0.31 EPS for the current year.

Institutional Trading of Puma Biotechnology

Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its holdings in Puma Biotechnology by 103.9% during the 3rd quarter. Jane Street Group LLC now owns 32,129 shares of the biopharmaceutical company's stock worth $82,000 after acquiring an additional 16,374 shares during the last quarter. Barclays PLC grew its stake in shares of Puma Biotechnology by 146.5% during the third quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company's stock valued at $199,000 after purchasing an additional 46,370 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Puma Biotechnology by 169.5% in the third quarter. JPMorgan Chase & Co. now owns 48,493 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 30,499 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Puma Biotechnology by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company's stock valued at $75,000 after purchasing an additional 11,252 shares in the last quarter. Finally, Gateway Wealth Partners LLC bought a new position in Puma Biotechnology in the 4th quarter worth approximately $31,000. 61.29% of the stock is owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.